Infusion vs NAD+: Comparing the Indexed Record
A working comparison of Infusion against NAD+ begins with the indexed literature, not with catalogue description.
Compound profiles
Infusion in the indexed record
The literature on Infusion is an extensive body of work: 271,255 PubMed-indexed records, alongside 40,388 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Allergy Asthma Clin Immunol, Home Healthc Now, J Allergy Clin Immunol Pract, spanning 1996–2024.
- Update: The 2024 Infusion Therapy Standards of Practice — Home Healthc Now, 2024. PMID: 38975817
- Safety of Intravenous Iron Following Infusion Reactions — J Allergy Clin Immunol Pract, 2021. PMID: 33248279
- Monotherapy with infusion therapies – useful or not? — J Neural Transm (Vienna), 2024. PMID: 38967810
- Home infusion therapy — Semin Oncol Nurs, 1996. PMID: 8857688
NAD+ in the indexed record
NAD+ returns 76,583 indexed records on PubMed, an extensive record, alongside 749 registered studies on ClinicalTrials.gov.
Publications carrying this compound include Cell Metab, EMBO Mol Med, Nat Metab, spanning 2020–2024.
- NAD(+) metabolism and its roles in cellular processes during ageing — Nat Rev Mol Cell Biol, 2021. PMID: 33353981
- NAD(+) metabolism, stemness, the immune response, and cancer — Signal Transduct Target Ther, 2021. PMID: 33384409
- NAD(+) homeostasis in health and disease — Nat Metab, 2020. PMID: 32694684
- NAD(+) homeostasis in human health and disease — EMBO Mol Med, 2021. PMID: 34041853
How the literature differs
The indexed record is not symmetrical between these two compounds. Infusion carries 194,672 more indexed records than NAD+, which means published methodology, characterisation data and replication attempts are more readily located for Infusion. For a researcher planning a literature review, that asymmetry usually determines which compound has established reference protocols and which requires primary-source work.
Registered study counts (40,388 vs 749) track a different signal — formal study registration rather than published output — and the two figures frequently diverge.
Side-by-side research profile
| Parameter | Infusion | NAD+ |
|---|---|---|
| PubMed indexed records | 271,255 | 76,583 |
| Registered studies (ClinicalTrials.gov) | 40,388 | 749 |
| Literature depth | Extensive | Extensive |
| Handling class | Lyophilised powder | Lyophilised powder |
| Designation | Research use only | Research use only |
Classification and why it matters
Infusion and NAD+ sit in different structural classes, and that classification is what determines whether a published protocol for one has any bearing on the other. Peptide research compounds are grouped by sequence length, origin and the receptor families the literature associates with them — not by the outcome a reader might be looking for.
Reading across classes is the most common error in a literature review. A protocol developed for Infusion describes conditions validated for Infusion: concentration ranges, solvent choice, incubation windows and control selection were all established against that compound. Applying those same conditions to NAD+ without re-validation produces data that cannot be compared back to the source publication.
Where the two compounds are studied in overlapping models, the published work almost always treats them as separate arms rather than as substitutes. That separation is the useful signal: it indicates the research record does not consider them equivalent.
Verification and documentation
What is in the vial is established by lot-specific analytics, not by label text. HPLC gives purity as a share of total peak area; mass spectrometry confirms the molecular weight matches the intended sequence. Neither substitutes for the other.
Storage and stability
Lyophilised peptide is the stable form. Held sealed at -20°C and shielded from light, it tolerates long storage; once reconstituted that tolerance drops sharply and the working solution is treated as short-lived.
Each freeze-thaw cycle costs integrity, which is why reconstituted material is normally split into single-use aliquots.
Selecting between them for a study design
Infusion and NAD+ are not interchangeable. They differ in structural class and in the pathways the literature associates with each, so substituting one for the other changes what a model is actually measuring.
Where a protocol cites a specific compound, the cited compound is the one the published result applies to. Where no protocol exists, the compound with the deeper indexed record (Infusion) generally offers more methodological precedent.
Frequently asked questions
Which of Infusion or NAD+ has more published research?
Infusion, with 271,255 indexed PubMed records against 76,583.
What is the regulatory status of these compounds?
Neither is an approved drug. Both are supplied strictly for in-vitro laboratory research and are not intended for human or veterinary consumption.
How should these compounds be stored?
Lyophilised material is conventionally stored at -20°C protected from light. Reconstituted solution is far less stable and is held at 2-8°C for short-duration laboratory work only.
Are Infusion and NAD+ the same compound?
No. They are structurally distinct research compounds with separate literature records — 271,255 indexed records for Infusion and 76,583 for NAD+.
Related references
- NAD+ — product and lot documentation
- Certificate of analysis & purity testing
- Research reference index
Research use only. The compounds discussed are supplied for in-vitro laboratory research. They are not drugs, are not approved for the diagnosis, treatment, cure or prevention of any condition, and are not intended for human or veterinary consumption.